CBIO insider filings
CRESCENT BIOPHARMA, INC. — 44 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen CBIO transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 8 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 4 insiders — 853,450 shares, $12,375,025 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 9 legs across 7 filings by 7 insiders — 16,726 shares, $285,501 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
- Largest priced transaction: purchase of 853,450 shares @ $14.50 ($12,375,025) by Fairmount Funds Management LLC, filed 2026-07-20.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Fairmount Funds Management LLC — Director, 10% owner & Fairmount Healthcare Fund II L.P. — Director, 10% owner & Kiselak Tomas — Director, 10% owner & Harwin Peter Evan — Director, 10% owner | 1 | 1 leg · 853,450 sh · $12,375,025 | — | 1 |
| Brumm Joshua T — Chief Executive Officer, Director | 1 | — | 2 legs · 9,447 sh · $159,775 | — |
| McNeill Jonathan — President and COO | 1 | — | 2 legs · 4,570 sh · $77,235 | — |
| Pinkas Jan — Chief Scientific Officer | 1 | — | 1 leg · 658 sh · $11,778 | — |
| Im Ellie Eunkyung — Chief Medical Officer | 1 | — | 1 leg · 623 sh · $11,152 | — |
| Bispham Barbara Harlin — See Remarks | 1 | — | 1 leg · 620 sh · $11,098 | — |
| Scalzo Richard William — Chief Financial Officer | 1 | — | 1 leg · 568 sh · $10,167 | — |
| Lynch Ryan — See Remarks | 1 | — | 1 leg · 240 sh · $4,296 | — |
Recent insider filings — CRESCENT BIOPHARMA, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | McNeill Jonathan — President and COO | Sale (S): 731 @ $17.90 · Sale (S): 3,839 @ $16.71 | EDGAR |
| 2026-09-18 | 4 | Brumm Joshua T — Chief Executive Officer, Director | Sale (S): 1,610 @ $17.90 · Sale (S): 7,837 @ $16.71 | EDGAR |
| 2026-09-18 | 4 | Bispham Barbara Harlin — See Remarks | Sale (S): 620 @ $17.90 | EDGAR |
| 2026-09-18 | 4 | Scalzo Richard William — Chief Financial Officer | Sale (S): 568 @ $17.90 | EDGAR |
| 2026-09-18 | 4 | Im Ellie Eunkyung — Chief Medical Officer | Sale (S): 623 @ $17.90 | EDGAR |
| 2026-09-18 | 4 | Pinkas Jan — Chief Scientific Officer | Sale (S): 658 @ $17.90 | EDGAR |
| 2026-09-18 | 4 | Lynch Ryan — See Remarks | Sale (S): 240 @ $17.90 | EDGAR |
| 2026-07-20 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner Kiselak Tomas — Director, 10% owner Harwin Peter Evan — Director, 10% owner | Purchase (P): 853,450 @ $14.50 · Purchase (P): 525,897 (derivative) @ $14.50 | EDGAR |
| 2026-06-23 | 4 | Lynch Ryan — See Remarks | Sale (S): 465 @ $17.99 | EDGAR |
| 2026-06-23 | 4 | Pinkas Jan — Chief Scientific Officer | Sale (S): 1,288 @ $17.99 | EDGAR |
| 2026-06-23 | 4 | Scalzo Richard William — Chief Financial Officer | Sale (S): 1,112 @ $17.99 | EDGAR |
| 2026-06-23 | 4 | Bispham Barbara Harlin — See Remarks | Sale (S): 1,218 @ $17.99 | EDGAR |
| 2026-06-23 | 4 | Im Ellie Eunkyung — Chief Medical Officer | Sale (S): 1,219 @ $17.99 | EDGAR |
| 2026-06-23 | 4 | McNeill Jonathan — President and COO | Sale (S): 20,549 @ $17.99 | EDGAR |
| 2026-06-23 | 4 | Brumm Joshua T — Chief Executive Officer, Director | Sale (S): 42,305 @ $17.99 | EDGAR |
| 2026-06-03 | 4 | Violin Jonathan — Director | Grant/award (A): 11,050 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Lubner David Charles — Director | Grant/award (A): 11,050 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Balcom Alexandra — Director | Grant/award (A): 11,050 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Moran Susan — Director | Grant/award (A): 11,050 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner Harwin Peter Evan — Director, 10% owner Kiselak Tomas — Director, 10% owner | Grant/award (A): 11,050 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Pinkas Jan — Chief Scientific Officer | Grant/award (A): 17,507 · Grant/award (A): 5,000 · Grant/award (A): 70,025 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Doughty Christopher Grant — Chief Business Officer | Grant/award (A): 14,714 · Grant/award (A): 8,000 · Grant/award (A): 58,855 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Brumm Joshua T — Chief Executive Officer, Director | Grant/award (A): 45,117 · Grant/award (A): 10,000 · Grant/award (A): 180,467 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Scalzo Richard William — Chief Financial Officer | Grant/award (A): 14,422 · Grant/award (A): 5,000 · Grant/award (A): 57,688 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | McNeill Jonathan — President and COO | Grant/award (A): 19,507 · Grant/award (A): 6,000 · Grant/award (A): 78,029 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Im Ellie Eunkyung — Chief Medical Officer | Grant/award (A): 16,298 · Grant/award (A): 5,000 · Grant/award (A): 65,190 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Lynch Ryan — See Remarks | Grant/award (A): 8,378 · Grant/award (A): 4,000 · Grant/award (A): 33,512 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Bispham Barbara Harlin — See Remarks | Grant/award (A): 12,422 · Grant/award (A): 6,000 · Grant/award (A): 72,185 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | McNeill Jonathan — President and COO | Grant/award (A): 172,836 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Brumm Joshua T — Chief Executive Officer, Director | Grant/award (A): 345,672 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner Kiselak Tomas — Director, 10% owner Harwin Peter Evan — Director, 10% owner | Purchase (P): 1,360,000 @ $13.41 · Purchase (P): 131,434 (derivative) @ $13.41 | EDGAR |
| 2025-07-16 | 4 | Pinkas Jan — Chief Scientific Officer | Grant/award (A): 142,474 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Moran Susan — Director | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner Kiselak Tomas — Director, 10% owner Harwin Peter Evan — Director, 10% owner | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Violin Jonathan — Director | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Balcom Alexandra — Director | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Lubner David Charles — Director | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | BVF PARTNERS L P/IL — 10% owner BIOTECHNOLOGY VALUE FUND L P — 10% owner BVF I GP LLC — 10% owner BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC — 10% owner BVF INC/IL — 10% owner LAMPERT MARK N — 10% owner | Other (J): 657,308 · Other (J): 556,617 · Other (J): 56,079 · Other (J): 304,098 (derivative) · Other (J): 257,515 (derivative) · Other (J): 25,944 (derivative) | EDGAR |
| 2023-10-27 | 4 | GNI Hong Kong Ltd — 10% owner | Other (J): 5,371,304 · Other (J): 10,577 (derivative) | EDGAR |
| 2023-09-01 | 4 | Miller Seline E. — SVP Finance; Interim CFO & PAO | Disposition to issuer (D): 6.50 | EDGAR |
| 2023-09-01 | 4 | Hunt Andrea — Director | Disposition to issuer (D): 28.23 | EDGAR |
| 2023-09-01 | 4 | USMAN NASSIM — President & CEO, Director | Disposition to issuer (D): 24.54 · Disposition to issuer (D): 8.46 · Disposition to issuer (D): 1.17 | EDGAR |
| 2023-09-01 | 4 | GNI Group Ltd. — 10% owner GNI Hong Kong Ltd — 10% owner | Disposition to issuer (D): 895.22 · Disposition to issuer (D): 5,371.30 | EDGAR |
| 2023-09-01 | 4 | LAWLOR AUGUSTINE — Director | Disposition to issuer (D): 24.57 · Disposition to issuer (D): 24.21 | EDGAR |
Recent 8-K events — CRESCENT BIOPHARMA, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K/A | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-06-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CBIO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →